↓ Skip to main content

Deficient Adipogenesis of Scleroderma Patient and Healthy African American Monocytes

Overview of attention for article published in Frontiers in Pharmacology, April 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Deficient Adipogenesis of Scleroderma Patient and Healthy African American Monocytes
Published in
Frontiers in Pharmacology, April 2017
DOI 10.3389/fphar.2017.00174
Pubmed ID
Authors

Rebecca Lee, Charles Reese, Gustavo Carmen-Lopez, Beth Perry, Michael Bonner, Marina Zemskova, Carole L. Wilson, Kristi L. Helke, Richard M. Silver, Stanley Hoffman, Elena Tourkina

Abstract

Monocytes from systemic sclerosis (SSc, scleroderma) patients and healthy African Americans (AA) are deficient in the regulatory protein caveolin-1 leading to enhanced migration toward chemokines and fibrogenic differentiation. While dermal fibrosis is the hallmark of SSc, loss of subcutaneous adipose tissue is a lesser-known feature. To better understand the etiology of SSc and the predisposition of AA to SSc, we studied the adipogenic potential of SSc and healthy AA monocytes. The ability of SSc and healthy AA monocytes to differentiate into adipocyte-like cells (ALC) is inhibited compared to healthy Caucasian (C) monocytes. We validated that monocyte-derived ALCs are distinct from macrophages by flow cytometry and immunocytochemistry. Like their enhanced fibrogenic differentiation, their inhibited adipogenic differentiation is reversed by the caveolin-1 scaffolding domain peptide (CSD, a surrogate for caveolin-1). The altered differentiation of SSc and healthy AA monocytes is additionally regulated by peroxisome proliferator-activated receptor γ (PPARγ) which is also present at reduced levels in these cells. In vivo studies further support the importance of caveolin-1 and PPARγ in fibrogenesis and adipogenesis. In SSc patients, healthy AA, and mice treated systemically with bleomycin, adipocytes lose caveolin-1 and PPARγ and the subcutaneous adipose layer is diminished. CSD treatment of these mice leads to a reappearance of the caveolin-1+/PPARγ+/FABP4+ subcutaneous adipose layer. Moreover, many of these adipocytes are CD45+, suggesting they are monocyte derived. Tracing experiments with injected EGFP+ monocytes confirm that monocytes contribute to the repair of the adipose layer when it is damaged by bleomycin treatment. Our observations strongly suggest that caveolin-1 and PPARγ work together to maintain a balance between the fibrogenic and adipogenic differentiation of monocytes, that this balance is altered in SSc and in healthy AA, and that monocytes make a major contribution to the repair of the adipose layer.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Kazakhstan 1 4%
Unknown 23 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 25%
Other 3 13%
Student > Ph. D. Student 3 13%
Student > Postgraduate 2 8%
Librarian 1 4%
Other 3 13%
Unknown 6 25%
Readers by discipline Count As %
Medicine and Dentistry 8 33%
Biochemistry, Genetics and Molecular Biology 4 17%
Nursing and Health Professions 1 4%
Immunology and Microbiology 1 4%
Decision Sciences 1 4%
Other 3 13%
Unknown 6 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2017.
All research outputs
#20,412,387
of 22,962,258 outputs
Outputs from Frontiers in Pharmacology
#10,144
of 16,230 outputs
Outputs of similar age
#269,224
of 308,921 outputs
Outputs of similar age from Frontiers in Pharmacology
#132
of 202 outputs
Altmetric has tracked 22,962,258 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,230 research outputs from this source. They receive a mean Attention Score of 5.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,921 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 202 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.